SAN JOSE, Calif., July 22, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced that it is partnering with the VA Maryland Health Care System's Baltimore VA Medical Center and the Baltimore Research and Education Foundation, a non-profit affiliate, in its ongoing prostate cancer Cchek™ study. Led by Dr. Minhaj Siddiqui, chief of Urology at the VA Maryland Health Care System and Associate Professor and Director of Urologic Oncology and Robotic Surgery at the University of Maryland School of Medicine, study enrollment is expected to begin in August of this year and will include men who are at risk for prostate cancer in a yearlong study that seeks to advance the Check™ liquid biopsy for prostate cancer.
"We are pleased to be working with Dr. Siddiqui and the VA Maryland Health Care System as we continue development of our artificial intelligence based prostate cancer liquid biopsy," stated Dr. Amit Kumar, President and CEO of Anixa.
About Anixa Biosciences, Inc.
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutics portfolio includes a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T, and a cancer vaccine technology focused specifically on triple negative breast cancer (TNBC), the most lethal form of the disease. Anixa's diagnostics portfolio includes the CchekTM liquid biopsy technology, a series of inexpensive non-invasive blood tests for early detection of solid tumors based on the body's immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Additional information is available at www.anixa.com.
Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Sharen Tilman (Investors)
Johanna Bennett (Media)
View original content to download multimedia:http://www.prnewswire.com/news-releases/anixa-biosciences-announces-us-department-of-veterans-affairs-va-maryland-health-care-system-joins-cchek-prostate-cancer-study-300888285.html